Developer docs
API playgroundTry for free, no card

Search company profiles

Preferred Cell Systems

Full company profile

uuid02ls3sd

Namestring
Preferred Cell Systems
Legal namestring
Preferred Cell Systems
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Preferred Cell Systems™ is a privately held life sciences company headquartered in Colorado Springs, Colorado, that manufactures and sells proprietary in vitro assay kits, reagents, and culture media for stem cell research, cellular therapy, and toxicity testing. The company is the exclusive manufacturer and supplier of the assay and reagent portfolio originally developed by HemoGenix, with HemoGenix retaining contract research services on an adjacent basis. Its product architecture centers on the proprietary Suspension Expansion Culture™ (SEC™) technology, which replaces traditional methylcellulose-based colony-forming assays with suspension culture formats compatible with standard pipettes, and on three core detection chemistries: ATP bioluminescence (HALO®, HemoGLO™), resazurin/resorufin fluorescence (HemoFLUOR™, MultiCellGro™, ImmunoFluor™ family), and WST-1 tetrazolium absorbance (HemoLIGHT™).

The portfolio spans lympho-hematopoietic cell viability and proliferation assays, a standardized hematotoxicity platform (HALO®-Tox HT) reportedly used by half of the top 50 biopharmaceutical companies, dedicated toxicity assays for stem cell lines (STEMGlo-Tox HT) and immunotoxicity (ImmunoGlo-Tox HT), a 1-day cellular therapy quality assay (Keystone Assay™), and an organ-specific toxicology suite covering cardiotoxicity, hepatotoxicity, neurotoxicity, nephrotoxicity, dermal toxicity, intestinal toxicity, tumor cell toxicity, and mesenchymal toxicity. Supported species include human, mouse, rat, dog, horse, pig, sheep, and non-human primate.

The business is a B2B reagent and kit manufacturer operating a product-led growth motion: customers discover products through the company website, assisted search tools, instructional videos, and a direct e-commerce storefront, with international distribution via a published distributor network. Revenue is generated from one-time per-kit purchases priced from approximately $687 to over $6,000 per kit depending on assay complexity, species, cell population, and plate count. Customer segments span biopharmaceutical drug-development teams, academic and life sciences researchers, cellular therapy developers, and veterinary researchers, with no disclosed revenue, headcount, funding, or ownership data.

Short descriptiontext

Preferred Cell Systems manufactures proprietary in vitro assay kits, reagents, and culture media for lympho-hematopoietic stem and progenitor cell research, cellular therapy QC, and standardized toxicity testing, selling directly via e-commerce and international distributors to biopharmaceutical companies, academic researchers, and cellular therapy developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersColorado Springs, United States
HQ citystring
Colorado Springs
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell viability assays, stem cell research reagents, hematotoxicity testing kits, in vitro toxicity assays, ATP bioluminescence assays
Industry3 codes
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Stem Cell Assay Kits and Reagents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Assay Kits and Reagents
TypeOne Time License
Description

The company generates revenue from the sale of standardized in vitro assay kits and reagents. Products include HALO®, HemoGLO™, HemoFLUOR™, HemoLIGHT™, HemaToxFlow™, STEMGlo™-Tox HT, MultiCellGro™, and related reagent kits. Kits are sold with catalog numbers specifying cell type, species, formulation (low serum or serum-free), and plate count. Pricing is per kit (e.g., STEMGlo-Tox HT at $1,980.15, HemaToxFlow at ~$856-$972 depending on formulation).

preferred-cell-systems.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Single-assay kit pricing per catalog number
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Per-kit pricing; different catalog numbers for different cell types, species, and formulations. Price ranges from approximately $687 to over $6,000 depending on assay complexity and number of plates included.

preferred-cell-systems.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1HALO®
Description

Standardized and validated bioluminescence research assay platform for lympho-hematopoietic cells

preferred-cell-systems.com
+11 more records
Core offering1 text field

Preferred Cell Systems manufactures and sells standardized in vitro assay kits, reagents, and culture media built on proprietary Suspension Expansion Culture™ (SEC™) technology for measuring cell viability, proliferation, and cytotoxicity in lympho-hematopoietic stem and progenitor cells. Its portfolio spans ATP bioluminescence (HALO®, HemoGLO™), fluorescence (HemoFLUOR™), and absorbance (HemoLIGHT™) assay platforms, plus multi-lineage (MultiCellGro™), flow cytometry (HemaToxFlow™), and high-throughput toxicity (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT) assays serving biopharma, academic, cellular therapy, and veterinary researchers across 8 species.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • HALO®-Tox HT is used by half of the top 50 biopharmaceutical companies worldwide
+2 more records
Product overview1 text field

Preferred Cell Systems™ is a life sciences company that manufactures culture media, reagents, and in vitro assays for stem cell research, cellular therapy, and toxicity testing. The company's product portfolio centers on its proprietary Suspension Expansion Culture™ (SEC™) Technology platform, which replaces traditional methylcellulose-based colony-forming assays with faster, more objective, instrument-based assays. The core product line includes four main assay platforms: HALO® (standardized/validated ATP bioluminescence), HemoGLO™ (simplified ATP bioluminescence), HemoFLUOR™ (fluorescence), and HemoLIGHT™ (absorbance) — all for measuring lympho-hematopoietic cell viability and proliferation. Additional products include MultiCellGro™ for multi-lineage analysis, HemaToxFlow™ for flow cytometric analysis, and a comprehensive toxicity testing suite (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT). The company also offers the CentroLIA*pc* LB962 luminescence plate reader as an instrument accessory, along with cell expansion reagents and specialized media. Products support multiple species (human, mouse, primate, rat, dog, horse, pig, sheep) and various cell types including stem cells, progenitor cells, and immune cells.

Product and service1 record
1HALO® (Hematopoietic Assays via Luminescence Output)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Preferred Cell Systems is the exclusive manufacturer and supplier of all reagents and in vitro assays originally produced by HemoGenix. HemoGenix continues to provide contract research services. Both companies share phone numbers ((719) 264-6251 for Preferred Cell Systems, (719) 264-6250 for HemoGenix) and appear to have an operational relationship where HemoGenix originated the product line and PCS now manufactures and distributes the products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Charles River provides preclinical safety and toxicology services plus specialty research models (including stem cell and hematotoxicity assays). Comparable to PCS in the in vitro toxicology space, but as a much larger CRO rather than a pure reagent manufacturer.

TypeRegional player
Description

HemoGenix is the company that originally developed the reagents and assays now exclusively manufactured by PCS; it currently focuses on contract research services (CRO). Highly comparable as the origin of PCS's product line and the implicit R&D partner, though HemoGenix operates as a service provider rather than a product manufacturer.

TypeBroad incumbent
Description

Promega is a major life sciences tools company offering ATP bioluminescence assays (CellTiter-Glo®) for cell viability. Comparable to PCS because it serves the same research market with similar core technology (ATP-based viability/toxicity readouts), but operates at vastly larger scale with broader product portfolio.

TypeBroad incumbent
Description

Bio-Techne offers cell biology reagents, stem cell research tools, and assay kits through brands like R&D Systems and Tocris. Comparable to PCS as a broader life sciences reagent supplier with overlapping cell viability and proliferation product lines, though Bio-Techne is a much larger, diversified public company.

TypeEmerging player
Description

Cisbio (part of Revvity) provides HTRF® cell-based assays for GPCR and kinase research, including viability and cytotoxicity readouts. Comparable to PCS as a specialized cell-based assay developer in the research/biopharma market.

TypeBroad incumbent
Description

Lonza Bioscience provides cell and gene therapy manufacturing tools, including potency and viability assays, alongside broader bioprocessing offerings. Comparable to PCS in cellular therapy QC and primary cell culture reagents, though Lonza operates at significantly larger scale across pharma services.

TypeBroad incumbent
Description

PerkinElmer (now Revvity) provides cell-based assay platforms, luminescence readers, and life sciences reagents for toxicity and cell viability testing. Comparable to PCS in offering both instruments and assay kits for cell-based readouts, though at a much larger scale.

TypeDirect peer
Description

STEMCELL Technologies is a leading developer of specialty reagents and assays for hematopoietic stem cell research, including colony-forming cell (CFC) assays that PCS's HALO® platform directly replaces. Highly comparable in target customer (stem cell and cellular therapy researchers) and product category (specialized stem cell assays).

TypeDirect peer
Description

CellGenix specializes in cell and gene therapy raw materials, including cytokines and cell culture reagents for hematopoietic cell therapy manufacturing. Comparable to PCS in serving the cellular therapy and regenerative medicine market with overlapping hematopoietic and immune cell reagents.

TypeBroad incumbent
Description

Thermo Fisher's Life Sciences division offers a broad portfolio of cell-based assays, viability reagents, and stem cell research tools. Comparable to PCS as an incumbent with overlapping cell biology and toxicology product lines, though much larger and more diversified.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Preferred Cell Systems

Stem Cell Assay Kits and Reagentspreferred-cell-systems.com

Preferred Cell Systems manufactures proprietary in vitro assay kits, reagents, and culture media for lympho-hematopoietic stem and progenitor cell research, cellular therapy QC, and standardized toxicity testing, selling directly via e-commerce and international distributors to biopharmaceutical companies, academic researchers, and cellular therapy developers.

What Preferred Cell Systems does

Preferred Cell Systems™ is a privately held life sciences company headquartered in Colorado Springs, Colorado, that manufactures and sells proprietary in vitro assay kits, reagents, and culture media for stem cell research, cellular therapy, and toxicity testing. The company is the exclusive manufacturer and supplier of the assay and reagent portfolio originally developed by HemoGenix, with HemoGenix retaining contract research services on an adjacent basis. Its product architecture centers on the proprietary Suspension Expansion Culture™ (SEC™) technology, which replaces traditional methylcellulose-based colony-forming assays with suspension culture formats compatible with standard pipettes, and on three core detection chemistries: ATP bioluminescence (HALO®, HemoGLO™), resazurin/resorufin fluorescence (HemoFLUOR™, MultiCellGro™, ImmunoFluor™ family), and WST-1 tetrazolium absorbance (HemoLIGHT™).

The portfolio spans lympho-hematopoietic cell viability and proliferation assays, a standardized hematotoxicity platform (HALO®-Tox HT) reportedly used by half of the top 50 biopharmaceutical companies, dedicated toxicity assays for stem cell lines (STEMGlo-Tox HT) and immunotoxicity (ImmunoGlo-Tox HT), a 1-day cellular therapy quality assay (Keystone Assay™), and an organ-specific toxicology suite covering cardiotoxicity, hepatotoxicity, neurotoxicity, nephrotoxicity, dermal toxicity, intestinal toxicity, tumor cell toxicity, and mesenchymal toxicity. Supported species include human, mouse, rat, dog, horse, pig, sheep, and non-human primate.

The business is a B2B reagent and kit manufacturer operating a product-led growth motion: customers discover products through the company website, assisted search tools, instructional videos, and a direct e-commerce storefront, with international distribution via a published distributor network. Revenue is generated from one-time per-kit purchases priced from approximately $687 to over $6,000 per kit depending on assay complexity, species, cell population, and plate count. Customer segments span biopharmaceutical drug-development teams, academic and life sciences researchers, cellular therapy developers, and veterinary researchers, with no disclosed revenue, headcount, funding, or ownership data.

Preferred Cell Systems firmographics

Firmographics
Name
Preferred Cell Systems
Legal name
Preferred Cell Systems
Website
https://preferred-cell-systems.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Preferred Cell Systems manufactures proprietary in vitro assay kits, reagents, and culture media for lympho-hematopoietic stem and progenitor cell research, cellular therapy QC, and standardized toxicity testing, selling directly via e-commerce and international distributors to biopharmaceutical companies, academic researchers, and cellular therapy developers.
Ownership category
akta.pro rank

Preferred Cell Systems industry classification

Industry
Product category
Stem Cell Assay Kits and Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell viability assays
  • Stem cell research reagents
  • Hematotoxicity testing kits
  • In vitro toxicity assays
  • ATP bioluminescence assays

Where Preferred Cell Systems is headquartered

Location

Headquarters

HQ city
Colorado Springs
HQ country
United States
HQ region
North America

Markets served

Preferred Cell Systems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Assay Kits and Reagents: The company generates revenue from the sale of standardized in vitro assay kits and reagents. Products include HALO®, HemoGLO™, HemoFLUOR™, HemoLIGHT™, HemaToxFlow™, STEMGlo™-Tox HT, MultiCellGro™, and related reagent kits. Kits are sold with catalog numbers specifying cell type, species, formulation (low serum or serum-free), and plate count. Pricing is per kit (e.g., STEMGlo-Tox HT at $1,980.15, HemaToxFlow at ~$856-$972 depending on formulation).

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSingle-assay kit pricing per catalog number

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Preferred Cell Systems product offering

Product offering

Core offering

Preferred Cell Systems manufactures and sells standardized in vitro assay kits, reagents, and culture media built on proprietary Suspension Expansion Culture™ (SEC™) technology for measuring cell viability, proliferation, and cytotoxicity in lympho-hematopoietic stem and progenitor cells. Its portfolio spans ATP bioluminescence (HALO®, HemoGLO™), fluorescence (HemoFLUOR™), and absorbance (HemoLIGHT™) assay platforms, plus multi-lineage (MultiCellGro™), flow cytometry (HemaToxFlow™), and high-throughput toxicity (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT) assays serving biopharma, academic, cellular therapy, and veterinary researchers across 8 species.

Product overview

Preferred Cell Systems™ is a life sciences company that manufactures culture media, reagents, and in vitro assays for stem cell research, cellular therapy, and toxicity testing. The company's product portfolio centers on its proprietary Suspension Expansion Culture™ (SEC™) Technology platform, which replaces traditional methylcellulose-based colony-forming assays with faster, more objective, instrument-based assays. The core product line includes four main assay platforms: HALO® (standardized/validated ATP bioluminescence), HemoGLO™ (simplified ATP bioluminescence), HemoFLUOR™ (fluorescence), and HemoLIGHT™ (absorbance) — all for measuring lympho-hematopoietic cell viability and proliferation. Additional products include MultiCellGro™ for multi-lineage analysis, HemaToxFlow™ for flow cytometric analysis, and a comprehensive toxicity testing suite (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT). The company also offers the CentroLIA*pc* LB962 luminescence plate reader as an instrument accessory, along with cell expansion reagents and specialized media. Products support multiple species (human, mouse, primate, rat, dog, horse, pig, sheep) and various cell types including stem cells, progenitor cells, and immune cells.

Differentiator

Problem solved

Functional benefit

Brands

  • HALO®: Standardized and validated bioluminescence research assay platform for lympho-hematopoietic cells
  • HemoGLO™
  • HemoFLUOR™
  • HemoLIGHT™
  • MultiCellGro™
  • HemaToxFlow™
  • HALO-Tox HT
  • ImmunoGlo™
  • ImmunoFluor™
  • LIVEGlo™
  • STEMGlo™-Tox HT
  • MultiCellGro™

Products and services

  • HALO® (Hematopoietic Assays via Luminescence Output)

Quantifiable outcome

  • HALO®-Tox HT is used by half of the top 50 biopharmaceutical companies worldwide
  • +2 more outcomes

Companies that use Preferred Cell Systems

Customer profile

Segments4 records

Ideal customer profiles4 records

Preferred Cell Systems technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature11 records

Preferred Cell Systems partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HemoGenixcoreTechnology or IntegrationPreferred Cell Systems is the exclusive manufacturer and supplier of all reagents and in vitro assays originally produced by HemoGenix. HemoGenix continues to provide contract research services. Both companies share phone numbers ((719) 264-6251 for Preferred Cell Systems, (719) 264-6250 for HemoGenix) and appear to have an operational relationship where HemoGenix originated the product line and PCS now manufactures and distributes the products.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Preferred Cell Systems competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Charles River provides preclinical safety and toxicology services plus specialty research models (including stem cell and hematotoxicity assays). Comparable to PCS in the in vitro toxicology space, but as a much larger CRO rather than a pure reagent manufacturer.
  • Promega Corporation: Promega is a major life sciences tools company offering ATP bioluminescence assays (CellTiter-Glo®) for cell viability. Comparable to PCS because it serves the same research market with similar core technology (ATP-based viability/toxicity readouts), but operates at vastly larger scale with broader product portfolio.
  • Bio-Techne (R&D Systems): Bio-Techne offers cell biology reagents, stem cell research tools, and assay kits through brands like R&D Systems and Tocris. Comparable to PCS as a broader life sciences reagent supplier with overlapping cell viability and proliferation product lines, though Bio-Techne is a much larger, diversified public company.
  • Lonza Bioscience: Lonza Bioscience provides cell and gene therapy manufacturing tools, including potency and viability assays, alongside broader bioprocessing offerings. Comparable to PCS in cellular therapy QC and primary cell culture reagents, though Lonza operates at significantly larger scale across pharma services.
  • PerkinElmer (Revvity): PerkinElmer (now Revvity) provides cell-based assay platforms, luminescence readers, and life sciences reagents for toxicity and cell viability testing. Comparable to PCS in offering both instruments and assay kits for cell-based readouts, though at a much larger scale.
  • Thermo Fisher Scientific (Life Sciences Solutions): Thermo Fisher's Life Sciences division offers a broad portfolio of cell-based assays, viability reagents, and stem cell research tools. Comparable to PCS as an incumbent with overlapping cell biology and toxicology product lines, though much larger and more diversified.

Regional players

  • HemoGenix: HemoGenix is the company that originally developed the reagents and assays now exclusively manufactured by PCS; it currently focuses on contract research services (CRO). Highly comparable as the origin of PCS's product line and the implicit R&D partner, though HemoGenix operates as a service provider rather than a product manufacturer.

Emerging players

  • Cisbio (Revvity): Cisbio (part of Revvity) provides HTRF® cell-based assays for GPCR and kinase research, including viability and cytotoxicity readouts. Comparable to PCS as a specialized cell-based assay developer in the research/biopharma market.

Direct peers

  • STEMCELL Technologies: STEMCELL Technologies is a leading developer of specialty reagents and assays for hematopoietic stem cell research, including colony-forming cell (CFC) assays that PCS's HALO® platform directly replaces. Highly comparable in target customer (stem cell and cellular therapy researchers) and product category (specialized stem cell assays).
  • CellGenix: CellGenix specializes in cell and gene therapy raw materials, including cytokines and cell culture reagents for hematopoietic cell therapy manufacturing. Comparable to PCS in serving the cellular therapy and regenerative medicine market with overlapping hematopoietic and immune cell reagents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Preferred Cell Systems social profiles

Digital presence

Preferred Cell Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Preferred Cell Systems leadership team

Management profile

Number of profiles

Preferred Cell Systems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Preferred Cell Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Preferred Cell Systems

What does Preferred Cell Systems do?

Preferred Cell Systems manufactures and sells standardized in vitro assay kits, reagents, and culture media built on proprietary Suspension Expansion Culture™ (SEC™) technology for measuring cell viability, proliferation, and cytotoxicity in lympho-hematopoietic stem and progenitor cells. Its portfolio spans ATP bioluminescence (HALO®, HemoGLO™), fluorescence (HemoFLUOR™), and absorbance (HemoLIGHT™) assay platforms, plus multi-lineage (MultiCellGro™), flow cytometry (HemaToxFlow™), and high-throughput toxicity (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT) assays serving biopharma, academic, cellular therapy, and veterinary researchers across 8 species.

Is Preferred Cell Systems a public or private company?

Preferred Cell Systems is a private company. It is classified as unknown and is currently operating.

When was Preferred Cell Systems founded?

Preferred Cell Systems was founded in 2017. It employs 1 to 10 people.

Where is Preferred Cell Systems based?

Preferred Cell Systems is headquartered in Colorado Springs, United States, in the North America region.

How does Preferred Cell Systems make money?

One revenue line is on record: assay Kits and Reagents.

Who are Preferred Cell Systems's main competitors?

Broad incumbents on record are Charles River Laboratories, Promega Corporation, Bio-Techne (R&D Systems), Lonza Bioscience, PerkinElmer (Revvity) and Thermo Fisher Scientific (Life Sciences Solutions). HemoGenix is listed as a regional player. Cisbio (Revvity) is listed as an emerging player. Direct peers are STEMCELL Technologies and CellGenix.

Does Preferred Cell Systems have an API?

No public API is recorded for Preferred Cell Systems.

What industry is Preferred Cell Systems in?

Preferred Cell Systems's product category is Stem Cell Assay Kits and Reagents. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales